Associate Professor David A Taylor

Associate Dean (Research Training)

BSc(Hons) University of Melbourne
PhD University of Melbourne

Telephone: +61 3 9903 9568
Fax: +61 3 9903 9638
Email: david.taylor@pharm.monash.edu.au

Medicinal Chemistry and Drug Action, Monash Institute of Pharmaceutical Sciences

• Mental health disorders (schizophrenia, drug addiction)
• Cannabinoids
• Addiction neurochemistry
• Opioid replacement therapies

Education

• Unit coordinator, VCP 3041 Pharmacology IIA, Bachelor of Pharmacy 
• Replacement of animals in teaching
• Honours streaming
• Recruitment of honours and HDR students
• Use of multimedia in teaching

Representative publications

1. Capuano B, Crosby IT, Lloyd EJ, Podloucka A, Taylor DA. Synthesis and Preliminary Pharmacological Evaluation of 4 '-Arylalkyl Analogues of Clozapine. IV. The Effects of Aromaticity and Isosteric Replacement. Australian Journal of Chemistry. 2008; 61:930-940.
2. Capuano B, Crosby IT, Lloyd EJ, Neve JE, Taylor DA. Aminimides as potential CNS-acting agents. III. Design, synthesis, and receptor binding of aminimide analogues of dopamine, serotonin, morphine, and nicotine . Australian Journal of Chemistry. 2008; 61:422-431.
3. Nielsen S, Dietze P, Cantwell K, Lee N, Taylor DA. Methadone and Buprenorphine related ambulance attendances: A population-based indicator of adverse events. Journal of Substance Abuse Treatment. 2008; 35:457-461.
4. Malone DT, Kearn CS, Chongue L, Mackie K, Taylor DA. Effect of social isolation on CB₁ and D₂ receptor and fatty acid amide hydrolase expression in rats. Neuroscience. 2008; 152:265-272.
5. Capuano B, Crosby IT, Lloyd EJ, Neve JE, Taylor DA. Aminimides as Potential CNS Acting Agents. II. Design, Synthesis and Receptor Binding of 4'-Arylalkyl Aminimide Analogues of Clozapine as Prospective Novel Antipsychotics. Australian Journal of Chemistry. 2008; 61:5-10.
6. Capuano B, Crosby IT, Lloyd EJ, Taylor DA. Synthesis and Preliminary Pharmacological Evaluation of 4'‑Arylalkyl Analogues of Clozapine. III. Replacement of the Tricyclic Nucleus with a Bicyclic Template. Australian Journal of Chemistry. 2007; 60:928-933.
7. Nielson S, Dietze P, Lee N, Dunlop A, Taylor DA. Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction. 2007; 102:616-622.
8. Nielsen S, Dietze P, Dunlop A, Muhleisen P, Taylor DA, et.al. Buprenorphine Supply by Community Pharmacists in Victoria, Australia: Perceptions, Experiences and Key Issues Identified. Drug and Alcohol Review. 2007; 26: 143-151.
9. Jazayeri JA, DeWeerd N, Raye W, Santos L, Taylor DA, et.al. Generation of mutant leukaemia inhibitory factor (LIF)-IgG heavy chain fusion proteins as bivalent antagonists of LIF. Journal of Immunological Methods. 2007; 323:1-10
10. Capuano B, Crosby IT, Lloyd EJ, Neve JE, Taylor DA. Aminimides as Potential CNS Acting Agents. I. Design, Synthesis and Receptor Binding of 4'-Aryl Aminimide Analogues of Clozapine as Prospective Novel Antipsychotics. Australian Journal of Chemistry. 2007; 60: 673-684. 
11. Malone DT, Taylor DA. The effect of D⁹- tetrahydrocannabinol on sensorimotor gating in socially isolated rats. Behavioural Brain Research. 2006; 166(1):101-109.   
12. Long LE, Malone DT, Taylor DA. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology. 2006; 31: 795-803.                  
13. Nielsen S, Taylor DA. The effect of buprenorphine and benzodiazepines on respiration in the rat. Drug and Alcohol Dependence. 2005; 79:95-101.   
14. Nielsen S, Muhleisen P, Taylor D, Dunlop A, Dietze P, Lee N. Preliminary findings on concurrent buprenorphine and benzodiazepine use in Victoria. Australian Pharmacist. 2005; 24: 488-489.
15. Long LE, Malone DT, Taylor DA. The pharmacological actions of Cannabidiol. Drugs of the Future. 2005; 30(7):747-754.
16. Malone DT, Long L, Taylor DA. The effect of SR 141617 and apomorphine on sensorimotor gating in Swiss mice. Pharmacology, Biochemistry and Behaviour. 2004; 77: 839-845.